{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:05:27Z","timestamp":1779426327001,"version":"3.53.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00259-025-07727-9","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:21:05Z","timestamp":1771287665000},"page":"4506-4520","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of TMTV and Dmax calculated from 18F-fluorodeoxyglucose positron emission tomography images in metastatic cutaneous melanoma treated with immune checkpoint blockade"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1357-1120","authenticated-orcid":false,"given":"Karim","family":"Amrane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Cabarrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coline","family":"Le Meur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bourhis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Pradier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Misery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Legoupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges-Philippe","family":"Fontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Salaun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ir\u00e8ne","family":"Buvat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Orlhac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Abgral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"7727_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9040063","volume":"9","author":"K Saginala","year":"2021","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Barsouk A. Epidemiology of melanoma. Med Sci (Basel). 2021;9:63. https:\/\/doi.org\/10.3390\/medsci9040063.","journal-title":"Med Sci (Basel)"},{"key":"7727_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104276","volume":"196","author":"A Boutros","year":"2024","unstructured":"Boutros A, Croce E, Ferrari M, Gili R, Massaro G, Marconcini R, et al. The treatment of advanced melanoma: current approaches and new challenges. Crit Rev Oncol Hematol. 2024;196:104276. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104276.","journal-title":"Crit Rev Oncol Hematol"},{"key":"7727_CR3","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1200\/JCO.20.00995","volume":"38","author":"C Robert","year":"2020","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, et al. Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma. J Clin Oncol. 2020;38:3937\u201346. https:\/\/doi.org\/10.1200\/JCO.20.00995.","journal-title":"J Clin Oncol"},{"key":"7727_CR4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407417","author":"JD Wolchok","year":"2024","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2407417.","journal-title":"N Engl J Med"},{"key":"7727_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000948","volume":"8","author":"O Michielin","year":"2020","unstructured":"Michielin O, Atkins MB, Koon HB, Dummer R, Ascierto PA. Evolving impact of long-term survival results on metastatic melanoma treatment. J Immunother Cancer. 2020;8:e000948. https:\/\/doi.org\/10.1136\/jitc-2020-000948.","journal-title":"J Immunother Cancer"},{"key":"7727_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s00259-019-04553-8","volume":"47","author":"P-Y Sala\u00fcn","year":"2020","unstructured":"Sala\u00fcn P-Y, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, et al. Good clinical practice recommendations for the use of PET\/CT in oncology. Eur J Nucl Med Mol Imaging. 2020;47:28\u201350. https:\/\/doi.org\/10.1007\/s00259-019-04553-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7727_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cpet.2019.08.007","volume":"15","author":"RJ Hicks","year":"2020","unstructured":"Hicks RJ, Iravani A, Sandhu S. 18F-fluorodeoxyglucose positron emission tomography\/computed tomography for assessing tumor response to immunotherapy in solid tumors: melanoma and beyond. PET Clin. 2020;15:11\u201322. https:\/\/doi.org\/10.1016\/j.cpet.2019.08.007.","journal-title":"PET Clin"},{"key":"7727_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103044","volume":"153","author":"C Bisschop","year":"2020","unstructured":"Bisschop C, de Heer EC, Brouwers AH, Hospers GaP, Jalving M. Rational use of 18F-FDG PET\/CT in patients with advanced cutaneous melanoma: a systematic review. Crit Rev Oncol Hematol. 2020;153:103044. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103044.","journal-title":"Crit Rev Oncol Hematol"},{"key":"7727_CR9","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1053\/j.semnuclmed.2021.06.010","volume":"51","author":"C de Van Wiele","year":"2021","unstructured":"de Van Wiele C, Juanito G, Vander BK, Lawal I, Sathekge M, Maes A, et al. Practical considerations when interpreting FDG PET\/CT imaging for staging and treatment response assessment in melanoma patients. Semin Nucl Med. 2021;51:544\u201353. https:\/\/doi.org\/10.1053\/j.semnuclmed.2021.06.010.","journal-title":"Semin Nucl Med"},{"key":"7727_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40644-024-00732-5","volume":"24","author":"K Amrane","year":"2024","unstructured":"Amrane K, Meur CL, Thuillier P, Berthou C, Uguen A, Deandreis D, et al. Review on radiomic analysis in 18F-fluorodeoxyglucose positron emission tomography for prediction of melanoma outcomes. Cancer Imaging. 2024;24:87. https:\/\/doi.org\/10.1186\/s40644-024-00732-5.","journal-title":"Cancer Imaging"},{"key":"7727_CR11","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.221180","volume":"307","author":"A Iravani","year":"2023","unstructured":"Iravani A, Wallace R, Lo SN, Galligan A, Weppler AM, Hicks RJ, et al. FDG PET\/CT prognostic markers in patients with advanced melanoma treated with ipilimumab and nivolumab. Radiology. 2023;307:e221180. https:\/\/doi.org\/10.1148\/radiol.221180.","journal-title":"Radiology"},{"key":"7727_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164083","volume":"15","author":"I Dirks","year":"2023","unstructured":"Dirks I, Keyaerts M, Dirven I, Neyns B, Vandemeulebroucke J. Development and validation of a predictive model for metastatic melanoma patients treated with pembrolizumab based on automated analysis of whole-body [18F]FDG PET\/CT imaging and clinical features. Cancers (Basel). 2023;15:4083. https:\/\/doi.org\/10.3390\/cancers15164083.","journal-title":"Cancers (Basel)"},{"key":"7727_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12092102","volume":"12","author":"T K\u00fcstner","year":"2022","unstructured":"K\u00fcstner T, Vogel J, Hepp T, Forschner A, Pfannenberg C, Schmidt H, et al. Development of a hybrid-imaging-based prognostic index for metastasized-melanoma patients in whole-body 18F-FDG PET\/CT and PET\/MRI data. Diagnostics. 2022;12:2102. https:\/\/doi.org\/10.3390\/diagnostics12092102.","journal-title":"Diagnostics"},{"key":"7727_CR14","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00259-019-04411-7","volume":"46","author":"R-D Seban","year":"2019","unstructured":"Seban R-D, Nemer JS, Marabelle A, Yeh R, Deutsch E, Ammari S, et al. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. Eur J Nucl Med Mol Imaging. 2019;46:2298\u2013310. https:\/\/doi.org\/10.1007\/s00259-019-04411-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7727_CR15","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00259-020-04757-3","volume":"47","author":"R-D Seban","year":"2020","unstructured":"Seban R-D, Moya-Plana A, Antonios L, Yeh R, Marabelle A, Deutsch E, et al. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4. Eur J Nucl Med Mol Imaging. 2020;47:2301\u201312. https:\/\/doi.org\/10.1007\/s00259-020-04757-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7727_CR16","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1007\/s00259-018-4211-0","volume":"46","author":"K Ito","year":"2019","unstructured":"Ito K, Sch\u00f6der H, Teng R, Humm JL, Ni A, Wolchok JD, et al. Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in melanoma patients treated with ipilimumab therapy. Eur J Nucl Med Mol Imaging. 2019;46:930\u20139. https:\/\/doi.org\/10.1007\/s00259-018-4211-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7727_CR17","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3390\/curroncol28030152","volume":"28","author":"S Vermeulen","year":"2021","unstructured":"Vermeulen S, Awada G, Keyaerts M, Neyns B, Everaert H. Early reassessment of total metabolic tumor volume on FDG-PET\/CT in advanced melanoma patients treated with pembrolizumab predicts long-term outcome. Curr Oncol. 2021;28:1630\u201340. https:\/\/doi.org\/10.3390\/curroncol28030152.","journal-title":"Curr Oncol"},{"key":"7727_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133190","volume":"14","author":"A Rivas","year":"2022","unstructured":"Rivas A, Delyon J, Martineau A, Blanc E, Allayous C, Da Meda L, et al. 18FDG PET assessment of therapeutic response in patients with advanced or metastatic melanoma treated with first-line immune checkpoint inhibitors. Cancers (Basel). 2022;14:3190. https:\/\/doi.org\/10.3390\/cancers14133190.","journal-title":"Cancers (Basel)"},{"key":"7727_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020168","volume":"13","author":"G Awada","year":"2021","unstructured":"Awada G, Jansen Y, Schwarze JK, Tijtgat J, Hellinckx L, Gondry O, et al. A comprehensive analysis of baseline clinical characteristics and biomarkers associated with outcome in advanced melanoma patients treated with pembrolizumab. Cancers (Basel). 2021;13:168. https:\/\/doi.org\/10.3390\/cancers13020168.","journal-title":"Cancers (Basel)"},{"key":"7727_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2967\/jnumed.119.229450","volume":"61","author":"A-S Cottereau","year":"2020","unstructured":"Cottereau A-S, Nioche C, Dirand A-S, Clerc J, Morschhauser F, Casasnovas O, et al. 18F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome. J Nucl Med. 2020;61:40\u20135. https:\/\/doi.org\/10.2967\/jnumed.119.229450.","journal-title":"J Nucl Med"},{"key":"7727_CR21","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","volume":"32","author":"A-S Cottereau","year":"2021","unstructured":"Cottereau A-S, Meignan M, Nioche C, Capobianco N, Clerc J, Chartier L, et al. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT\u2020. Ann Oncol. 2021;32:404\u201311. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.019.","journal-title":"Ann Oncol"},{"key":"7727_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12880-023-01138-8","volume":"23","author":"J Dang","year":"2023","unstructured":"Dang J, Peng X, Wu P, Yao Y, Tan X, Ye Z, et al. Predictive value of Dmax and %\u0394SUVmax of 18F-FDG PET\/CT for the prognosis of patients with diffuse large B-cell lymphoma. BMC Med Imaging. 2023;23:173. https:\/\/doi.org\/10.1186\/s12880-023-01138-8.","journal-title":"BMC Med Imaging"},{"key":"7727_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092494","volume":"15","author":"D Albano","year":"2023","unstructured":"Albano D, Treglia G, Dondi F, Calabr\u00f2 A, Rizzo A, Annunziata S, et al. 18F-FDG PET\/CT maximum tumor dissemination (Dmax) in lymphoma: a new prognostic factor? Cancers (Basel). 2023;15:2494. https:\/\/doi.org\/10.3390\/cancers15092494.","journal-title":"Cancers (Basel)"},{"key":"7727_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2023.110798","volume":"163","author":"H Xu","year":"2023","unstructured":"Xu H, Ma J, Yang G, Xiao S, Li W, Sun Y, et al. Prognostic value of metabolic tumor volume and lesion dissemination from baseline PET\/CT in patients with diffuse large B-cell lymphoma: further risk stratification of the group with low-risk and high-risk NCCN-IPI. Eur J Radiol. 2023;163:110798. https:\/\/doi.org\/10.1016\/j.ejrad.2023.110798.","journal-title":"Eur J Radiol"},{"key":"7727_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00259-023-06427-6","volume":"51","author":"E Marchal","year":"2024","unstructured":"Marchal E, Palard-Novello X, Lhomme F, Meyer ME, Manson G, Devillers A, et al. Baseline [18F]FDG PET features are associated with survival and toxicity in patients treated with CAR T cells for large B cell lymphoma. Eur J Nucl Med Mol Imaging. 2024;51:481\u20139. https:\/\/doi.org\/10.1007\/s00259-023-06427-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7727_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06929-x","author":"R-D Seban","year":"2024","unstructured":"Seban R-D, Champion L, De Moura A, Lerebours F, Loirat D, Pierga J-Y, et al. Pre-treatment [18F]FDG PET\/CT biomarkers for the prediction of antibody-drug conjugates efficacy in metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-06929-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7727_CR27","unstructured":"Orlhac F, Baghdasarian NH, Fokem-Fosso H, Luporsi M, Tissot H, Nioche C, et al. Quantification of lesion dissemination (Dmax) in [18F]FDG-PET\/CT imaging: a prognostic factor complementary to Total Metabolic Tumor Volume (TMTV) for advanced non-small cell lung cancer patients. Journal of Nuclear Medicine. Society of Nuclear Medicine; 2024;65:241937\u2013241937."},{"key":"7727_CR28","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s11307-016-0940-2","volume":"18","author":"FHP van Velden","year":"2016","unstructured":"van Velden FHP, Kramer GM, Frings V, Nissen IA, Mulder ER, de Langen AJ, et al. Repeatability of radiomic features in non-small-cell lung cancer [(18)F]FDG-PET\/CT studies: impact of reconstruction and delineation. Mol Imaging Biol. 2016;18:788\u201395. https:\/\/doi.org\/10.1007\/s11307-016-0940-2.","journal-title":"Mol Imaging Biol"},{"key":"7727_CR29","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1007\/s00330-017-4859-z","volume":"27","author":"I Shiri","year":"2017","unstructured":"Shiri I, Rahmim A, Ghaffarian P, Geramifar P, Abdollahi H, Bitarafan-Rajabi A. The impact of image reconstruction settings on 18F-FDG PET radiomic features: multi-scanner phantom and patient studies. Eur Radiol. 2017;27:4498\u2013509. https:\/\/doi.org\/10.1007\/s00330-017-4859-z.","journal-title":"Eur Radiol"},{"key":"7727_CR30","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245\u201351. https:\/\/doi.org\/10.1016\/0895-4356(94)90129-5.","journal-title":"J Clin Epidemiol"},{"key":"7727_CR31","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","volume":"18","author":"EZ Keung","year":"2018","unstructured":"Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018;18:775\u201384. https:\/\/doi.org\/10.1080\/14737140.2018.1489246.","journal-title":"Expert Rev Anticancer Ther"},{"key":"7727_CR32","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7727_CR33","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","volume":"78","author":"C Nioche","year":"2018","unstructured":"Nioche C, Orlhac F, Boughdad S, Reuz\u00e9 S, Goya-Outi J, Robert C, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78:4786\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0125.","journal-title":"Cancer Res"},{"key":"7727_CR34","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/0284186X.2020.1712473","volume":"59","author":"JC Moser","year":"2020","unstructured":"Moser JC, Wei G, Colonna SV, Grossmann KF, Patel S, Hyngstrom JR. Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma. Acta Oncol. 2020;59:434\u20137. https:\/\/doi.org\/10.1080\/0284186X.2020.1712473.","journal-title":"Acta Oncol"},{"key":"7727_CR35","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/CMR.0000000000000885","volume":"33","author":"B Cybulska-Stopa","year":"2023","unstructured":"Cybulska-Stopa B, Piejko K, Ostaszewski K, Dziura R, Galus \u0141, Zi\u00f3\u0142kowska B, et al. Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment. Melanoma Res. 2023;33:208\u201317. https:\/\/doi.org\/10.1097\/CMR.0000000000000885.","journal-title":"Melanoma Res"},{"key":"7727_CR36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","volume":"52","author":"H-J Im","year":"2018","unstructured":"Im H-J, Bradshaw T, Solaiyappan M, Cho SY. Current methods to define metabolic tumor volume in positron emission tomography: which one is better? Nucl Med Mol Imaging. 2018;52:5\u201315. https:\/\/doi.org\/10.1007\/s13139-017-0493-6.","journal-title":"Nucl Med Mol Imaging"},{"key":"7727_CR37","doi-asserted-by":"publisher","first-page":"21570","DOI":"10.1038\/s41598-025-95713-4","volume":"15","author":"H Saadani","year":"2025","unstructured":"Saadani H, Aalbersberg EA, Kayembe MT, Haanen JBAG, Hoekstra OS, Boellaard R, et al. Pretreatment PET dissemination features as biomarkers for survival outcomes in melanoma patients treated with immune-checkpoint inhibitors. Sci Rep. 2025;15:21570. https:\/\/doi.org\/10.1038\/s41598-025-95713-4.","journal-title":"Sci Rep"},{"key":"7727_CR38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40644-024-00727-2","volume":"24","author":"C Lasnon","year":"2024","unstructured":"Lasnon C, Morel A, Aide N, Silva AD, Emile G. Baseline and early 18F-FDG PET\/CT evaluations as predictors of progression-free survival in metastatic breast cancer patients treated with targeted anti-CDK therapy. Cancer Imaging. 2024;24:90. https:\/\/doi.org\/10.1186\/s40644-024-00727-2.","journal-title":"Cancer Imaging"},{"key":"7727_CR39","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s00259-020-04792-0","volume":"47","author":"R Nakamoto","year":"2020","unstructured":"Nakamoto R, Zaba LC, Rosenberg J, Reddy SA, Nobashi TW, Davidzon G, et al. Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. Eur J Nucl Med Mol Imaging. 2020;47:2787\u201395. https:\/\/doi.org\/10.1007\/s00259-020-04792-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7727_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2021.110107","volume":"146","author":"G Schweighofer-Zwink","year":"2022","unstructured":"Schweighofer-Zwink G, Manafi-Farid R, K\u00f6lblinger P, Hehenwarter L, Harsini S, Pirich C, et al. Prognostic value of 2-[18F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy. Eur J Radiol. 2022;146:110107. https:\/\/doi.org\/10.1016\/j.ejrad.2021.110107.","journal-title":"Eur J Radiol"},{"key":"7727_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007628","volume":"12","author":"P Tricarico","year":"2024","unstructured":"Tricarico P, Chardin D, Martin N, Contu S, Hugonnet F, Otto J, et al. Total metabolic tumor volume on 18F-FDG PET\/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy. J Immunother Cancer. 2024;12:e007628. https:\/\/doi.org\/10.1136\/jitc-2023-007628.","journal-title":"J Immunother Cancer"},{"key":"7727_CR42","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1097\/MNM.0000000000001625","volume":"43","author":"N Ag\u00fclo\u011flu","year":"2022","unstructured":"Ag\u00fclo\u011flu N, Aksu A, Unat DS, Akyol M. The prognostic relationship of 18F-FDG PET\/CT metabolic and volumetric parameters in metastatic ALK + NSCLC. Nucl Med Commun. 2022;43:1217\u201324. https:\/\/doi.org\/10.1097\/MNM.0000000000001625.","journal-title":"Nucl Med Commun"},{"key":"7727_CR43","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1503093.","journal-title":"N Engl J Med"},{"key":"7727_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113289","volume":"193","author":"M Fournier","year":"2023","unstructured":"Fournier M, Mortier L, Dereure O, Dalac S, Oriano B, Dalle S, et al. Hyperprogression in advanced melanoma is not restricted to immunotherapy. Eur J Cancer. 2023;193:113289. https:\/\/doi.org\/10.1016\/j.ejca.2023.113289.","journal-title":"Eur J Cancer"},{"key":"7727_CR45","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","volume":"17","author":"JS Weber","year":"2016","unstructured":"Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL, Lawrence DP, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016;17:943\u201355. https:\/\/doi.org\/10.1016\/S1470-2045(16)30126-7.","journal-title":"Lancet Oncol"},{"key":"7727_CR46","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_432462","volume":"44","author":"N Kidwai","year":"2024","unstructured":"Kidwai N, Chen M, Postow MA, Hassel J, Callahan M. Breaking the mold: trailblazing melanoma therapy beyond checkpoint through innovative approaches. Am Soc Clin Oncol Educ Book. 2024;44:e432462. https:\/\/doi.org\/10.1200\/EDBK_432462.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"7727_CR47","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","volume":"5","author":"PC Tumeh","year":"2017","unstructured":"Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res. 2017;5:417\u201324. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0325.","journal-title":"Cancer Immunol Res"},{"key":"7727_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70631","volume":"14","author":"Y Foerster","year":"2025","unstructured":"Foerster Y, Mayer K, Wasserer S, Dechant M, Verkhoturova V, Heyer S, et al. Elevated neutrophil-to-lymphocyte ratio correlates with liver metastases and poor immunotherapy response in stage IV melanoma. Cancer Med. 2025;14:e70631. https:\/\/doi.org\/10.1002\/cam4.70631.","journal-title":"Cancer Med"},{"key":"7727_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70923","volume":"14","author":"CB Nijboer","year":"2025","unstructured":"Nijboer CB, Piersma D, Sijben AEJ, Hoti B, van der Meulen M. The effect of concomitant immunotherapy and stereotactic radiotherapy, and of location on survival in patients with brain metastases from melanoma. Cancer Med. 2025;14:e70923. https:\/\/doi.org\/10.1002\/cam4.70923.","journal-title":"Cancer Med"},{"key":"7727_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114172","volume":"207","author":"RJ Verheijden","year":"2024","unstructured":"Verheijden RJ, Burgers FH, Janssen JC, Putker AE, Veenstra SPGR, Hospers GAP, et al. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma. Eur J Cancer. 2024;207:114172. https:\/\/doi.org\/10.1016\/j.ejca.2024.114172.","journal-title":"Eur J Cancer"},{"key":"7727_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1237643","volume":"13","author":"EA Janka","year":"2023","unstructured":"Janka EA, V\u00e1nyai B, Szab\u00f3 IL, Toka-Farkas T, V\u00e1rv\u00f6lgyi T, Kapit\u00e1ny A, et al. Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1. Front Oncol. 2023;13:1237643. https:\/\/doi.org\/10.3389\/fonc.2023.1237643.","journal-title":"Front Oncol"},{"key":"7727_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00534-9","volume":"8","author":"M Ligero","year":"2024","unstructured":"Ligero M, Gielen B, Navarro V, Cresta Morgado P, Prior O, Dienstmann R, et al. A whirl of radiomics-based biomarkers in cancer immunotherapy, why is large scale validation still lacking? npj Precis Oncol. 2024;8:42. https:\/\/doi.org\/10.1038\/s41698-024-00534-9.","journal-title":"npj Precis Oncol"},{"key":"7727_CR53","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/MNM.0000000000001543","volume":"43","author":"AK Jha","year":"2022","unstructured":"Jha AK, Mithun S, Purandare NC, Kumar R, Rangarajan V, Wee L, et al. Radiomics: a quantitative imaging biomarker in precision oncology. Nucl Med Commun. 2022;43:483\u201393. https:\/\/doi.org\/10.1097\/MNM.0000000000001543.","journal-title":"Nucl Med Commun"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07727-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07727-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07727-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:08:44Z","timestamp":1779422924000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07727-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7727"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07727-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and the 1964 Helsinki Declaration.MelBase is sponsored by the French National Cancer Institute and industrial partners and is administered by the Department of Clinical Research and Innovation of the Greater Paris University Hospitals (AP\u2010HP). The MelBase protocol was approved by the French Ethics Committee (CPP Ile\u2010de\u2010France XI, n_12027, 2012) and registered in the NIH clinical trials database (\n                      NCT02828202).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For living patients at the time of the study, written information regarding the research was provided to obtain their non-opposition to participation. For deceased patients, a waiver of information was granted by CCTIRS. Informed Consent (retrospective study): For living patients at the time of the study, written information regarding the research was provided to obtain their non-opposition to participation. For deceased patients, a waiver of information was granted by CCTIRS.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent (retrospective study)"}},{"value":"KA received honoraria from Astellas, MSD, BMS, and Pfizer. The other authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}